Molecular Bases of Drug Resistance in Hepatocellular Carcinoma
The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibi...
Gespeichert in:
| Veröffentlicht in: | Cancers 2020-06, Vol.12 (6), p.1663 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 1663 |
| container_title | Cancers |
| container_volume | 12 |
| creator | Marin, Jose J.G. Macias, Rocio I.R. Monte, Maria J. Romero, Marta R. Asensio, Maitane Sanchez-Martin, Anabel Cives-Losada, Candela Temprano, Alvaro G. Espinosa-Escudero, Ricardo Reviejo, Maria Bohorquez, Laura H. Briz, Oscar |
| description | The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the available information regarding our understanding of the molecular bases of mechanisms of chemoresistance (MOC) with a significant impact on the response of HCC to existing pharmacological tools, which include classical chemotherapeutic agents, TKIs and novel immune-sensitizing strategies. Many of the more than one hundred genes involved in seven MOC have been identified as potential biomarkers to predict the failure of treatment, as well as druggable targets to develop novel strategies aimed at increasing the sensitivity of HCC to pharmacological treatments. |
| doi_str_mv | 10.3390/cancers12061663 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7352164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2417924040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-1527bc26ede8d2d4ad0f54bdef0e5f78f4297db691521024049492e193ad313b3</originalsourceid><addsrcrecordid>eNpdkc1Lw0AQxRdRbKk9ew148RK7X9nNXgpaPypUBNHzstlMakqSrbuJ4H9vYoto5zID8-PNPB5C5wRfMabwzJrGgg-EYkGEYEdoTLGksRCKH_-ZR2gawgb3xRiRQp6iEaNJmqSKjdH8yVVgu8r46MYECJErolvfraMXCGVohwtR2URL2JrWWaiqH3RhvC0bV5szdFKYKsB03yfo7f7udbGMV88Pj4vrVWyZStuYJFRmlgrIIc1pzk2Oi4RnORQYkkKmBadK5plQPUgw5ZgrrigQxUzOCMvYBM13utsuqyG30LTeVHrry9r4L-1Mqf9vmvJdr92nlqxXFLwXuNwLePfRQWh1XYbBj2nAdUFTTlLCSCqTHr04QDeu801vb6CkGt7DPTXbUda7EDwUv88QrId49EE87BsczIIA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2417924040</pqid></control><display><type>article</type><title>Molecular Bases of Drug Resistance in Hepatocellular Carcinoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Marin, Jose J.G. ; Macias, Rocio I.R. ; Monte, Maria J. ; Romero, Marta R. ; Asensio, Maitane ; Sanchez-Martin, Anabel ; Cives-Losada, Candela ; Temprano, Alvaro G. ; Espinosa-Escudero, Ricardo ; Reviejo, Maria ; Bohorquez, Laura H. ; Briz, Oscar</creator><creatorcontrib>Marin, Jose J.G. ; Macias, Rocio I.R. ; Monte, Maria J. ; Romero, Marta R. ; Asensio, Maitane ; Sanchez-Martin, Anabel ; Cives-Losada, Candela ; Temprano, Alvaro G. ; Espinosa-Escudero, Ricardo ; Reviejo, Maria ; Bohorquez, Laura H. ; Briz, Oscar</creatorcontrib><description>The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the available information regarding our understanding of the molecular bases of mechanisms of chemoresistance (MOC) with a significant impact on the response of HCC to existing pharmacological tools, which include classical chemotherapeutic agents, TKIs and novel immune-sensitizing strategies. Many of the more than one hundred genes involved in seven MOC have been identified as potential biomarkers to predict the failure of treatment, as well as druggable targets to develop novel strategies aimed at increasing the sensitivity of HCC to pharmacological treatments.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12061663</identifier><identifier>PMID: 32585893</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Angiogenesis ; Cancer therapies ; Chemoresistance ; Chemotherapy ; Drug resistance ; Drug therapy ; Drugs ; Hepatocellular carcinoma ; Kinases ; Liver cancer ; Medical prognosis ; Metabolism ; Metabolites ; Plasma ; Proteins ; Review ; Tyrosine</subject><ispartof>Cancers, 2020-06, Vol.12 (6), p.1663</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-1527bc26ede8d2d4ad0f54bdef0e5f78f4297db691521024049492e193ad313b3</citedby><cites>FETCH-LOGICAL-c398t-1527bc26ede8d2d4ad0f54bdef0e5f78f4297db691521024049492e193ad313b3</cites><orcidid>0000-0001-6891-1554 ; 0000-0003-1186-6849 ; 0000-0002-4748-0326 ; 0000-0003-1844-7428</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352164/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352164/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Marin, Jose J.G.</creatorcontrib><creatorcontrib>Macias, Rocio I.R.</creatorcontrib><creatorcontrib>Monte, Maria J.</creatorcontrib><creatorcontrib>Romero, Marta R.</creatorcontrib><creatorcontrib>Asensio, Maitane</creatorcontrib><creatorcontrib>Sanchez-Martin, Anabel</creatorcontrib><creatorcontrib>Cives-Losada, Candela</creatorcontrib><creatorcontrib>Temprano, Alvaro G.</creatorcontrib><creatorcontrib>Espinosa-Escudero, Ricardo</creatorcontrib><creatorcontrib>Reviejo, Maria</creatorcontrib><creatorcontrib>Bohorquez, Laura H.</creatorcontrib><creatorcontrib>Briz, Oscar</creatorcontrib><title>Molecular Bases of Drug Resistance in Hepatocellular Carcinoma</title><title>Cancers</title><description>The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the available information regarding our understanding of the molecular bases of mechanisms of chemoresistance (MOC) with a significant impact on the response of HCC to existing pharmacological tools, which include classical chemotherapeutic agents, TKIs and novel immune-sensitizing strategies. Many of the more than one hundred genes involved in seven MOC have been identified as potential biomarkers to predict the failure of treatment, as well as druggable targets to develop novel strategies aimed at increasing the sensitivity of HCC to pharmacological treatments.</description><subject>Angiogenesis</subject><subject>Cancer therapies</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Hepatocellular carcinoma</subject><subject>Kinases</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Review</subject><subject>Tyrosine</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1Lw0AQxRdRbKk9ew148RK7X9nNXgpaPypUBNHzstlMakqSrbuJ4H9vYoto5zID8-PNPB5C5wRfMabwzJrGgg-EYkGEYEdoTLGksRCKH_-ZR2gawgb3xRiRQp6iEaNJmqSKjdH8yVVgu8r46MYECJErolvfraMXCGVohwtR2URL2JrWWaiqH3RhvC0bV5szdFKYKsB03yfo7f7udbGMV88Pj4vrVWyZStuYJFRmlgrIIc1pzk2Oi4RnORQYkkKmBadK5plQPUgw5ZgrrigQxUzOCMvYBM13utsuqyG30LTeVHrry9r4L-1Mqf9vmvJdr92nlqxXFLwXuNwLePfRQWh1XYbBj2nAdUFTTlLCSCqTHr04QDeu801vb6CkGt7DPTXbUda7EDwUv88QrId49EE87BsczIIA</recordid><startdate>20200623</startdate><enddate>20200623</enddate><creator>Marin, Jose J.G.</creator><creator>Macias, Rocio I.R.</creator><creator>Monte, Maria J.</creator><creator>Romero, Marta R.</creator><creator>Asensio, Maitane</creator><creator>Sanchez-Martin, Anabel</creator><creator>Cives-Losada, Candela</creator><creator>Temprano, Alvaro G.</creator><creator>Espinosa-Escudero, Ricardo</creator><creator>Reviejo, Maria</creator><creator>Bohorquez, Laura H.</creator><creator>Briz, Oscar</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6891-1554</orcidid><orcidid>https://orcid.org/0000-0003-1186-6849</orcidid><orcidid>https://orcid.org/0000-0002-4748-0326</orcidid><orcidid>https://orcid.org/0000-0003-1844-7428</orcidid></search><sort><creationdate>20200623</creationdate><title>Molecular Bases of Drug Resistance in Hepatocellular Carcinoma</title><author>Marin, Jose J.G. ; Macias, Rocio I.R. ; Monte, Maria J. ; Romero, Marta R. ; Asensio, Maitane ; Sanchez-Martin, Anabel ; Cives-Losada, Candela ; Temprano, Alvaro G. ; Espinosa-Escudero, Ricardo ; Reviejo, Maria ; Bohorquez, Laura H. ; Briz, Oscar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-1527bc26ede8d2d4ad0f54bdef0e5f78f4297db691521024049492e193ad313b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiogenesis</topic><topic>Cancer therapies</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Hepatocellular carcinoma</topic><topic>Kinases</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Review</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marin, Jose J.G.</creatorcontrib><creatorcontrib>Macias, Rocio I.R.</creatorcontrib><creatorcontrib>Monte, Maria J.</creatorcontrib><creatorcontrib>Romero, Marta R.</creatorcontrib><creatorcontrib>Asensio, Maitane</creatorcontrib><creatorcontrib>Sanchez-Martin, Anabel</creatorcontrib><creatorcontrib>Cives-Losada, Candela</creatorcontrib><creatorcontrib>Temprano, Alvaro G.</creatorcontrib><creatorcontrib>Espinosa-Escudero, Ricardo</creatorcontrib><creatorcontrib>Reviejo, Maria</creatorcontrib><creatorcontrib>Bohorquez, Laura H.</creatorcontrib><creatorcontrib>Briz, Oscar</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marin, Jose J.G.</au><au>Macias, Rocio I.R.</au><au>Monte, Maria J.</au><au>Romero, Marta R.</au><au>Asensio, Maitane</au><au>Sanchez-Martin, Anabel</au><au>Cives-Losada, Candela</au><au>Temprano, Alvaro G.</au><au>Espinosa-Escudero, Ricardo</au><au>Reviejo, Maria</au><au>Bohorquez, Laura H.</au><au>Briz, Oscar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Bases of Drug Resistance in Hepatocellular Carcinoma</atitle><jtitle>Cancers</jtitle><date>2020-06-23</date><risdate>2020</risdate><volume>12</volume><issue>6</issue><spage>1663</spage><pages>1663-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the available information regarding our understanding of the molecular bases of mechanisms of chemoresistance (MOC) with a significant impact on the response of HCC to existing pharmacological tools, which include classical chemotherapeutic agents, TKIs and novel immune-sensitizing strategies. Many of the more than one hundred genes involved in seven MOC have been identified as potential biomarkers to predict the failure of treatment, as well as druggable targets to develop novel strategies aimed at increasing the sensitivity of HCC to pharmacological treatments.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32585893</pmid><doi>10.3390/cancers12061663</doi><orcidid>https://orcid.org/0000-0001-6891-1554</orcidid><orcidid>https://orcid.org/0000-0003-1186-6849</orcidid><orcidid>https://orcid.org/0000-0002-4748-0326</orcidid><orcidid>https://orcid.org/0000-0003-1844-7428</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2020-06, Vol.12 (6), p.1663 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7352164 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Angiogenesis Cancer therapies Chemoresistance Chemotherapy Drug resistance Drug therapy Drugs Hepatocellular carcinoma Kinases Liver cancer Medical prognosis Metabolism Metabolites Plasma Proteins Review Tyrosine |
| title | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A24%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Bases%20of%20Drug%20Resistance%20in%20Hepatocellular%20Carcinoma&rft.jtitle=Cancers&rft.au=Marin,%20Jose%20J.G.&rft.date=2020-06-23&rft.volume=12&rft.issue=6&rft.spage=1663&rft.pages=1663-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12061663&rft_dat=%3Cproquest_pubme%3E2417924040%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2417924040&rft_id=info:pmid/32585893&rfr_iscdi=true |